Progyny (NASDAQ:PGNY) Stock Rating Lowered by Zacks Research

Progyny (NASDAQ:PGNY) was downgraded by equities research analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a report issued on Monday, Zacks reports.

Several other research firms also recently issued reports on PGNY. JPMorgan Chase & Co. lifted their price target on Progyny from $27.00 to $30.00 and gave the stock a “neutral” rating in a research note on Friday, August 21st. Leerink Partners set a $38.00 price objective on shares of Progyny in a research note on Wednesday, July 22nd. KeyCorp increased their price objective on shares of Progyny from $30.00 to $35.00 and gave the company an “overweight” rating in a research note on Monday, July 13th. Jefferies Financial Group set a $33.00 target price on shares of Progyny in a report on Tuesday, September 8th. Finally, Truist Financial raised their target price on shares of Progyny from $33.00 to $36.00 and gave the company a “buy” rating in a report on Thursday, August 13th. Nine investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $34.36.

Progyny Stock Performance

PGNY opened at $28.58 on Monday. The business’s fifty day moving average is $26.44 and its two-hundred day moving average is $25.67. The company has a market cap of $2.19 billion, a price-to-earnings ratio of 31.07, a PEG ratio of 1.92 and a beta of 1.02. Progyny has a one year low of $16.10 and a one year high of $33.06.

Progyny (NASDAQ:PGNY) last posted its earnings results on Thursday, August 6th. The company reported $0.55 earnings per share for the quarter, beating the consensus estimate of $0.33 by $0.22. The company had revenue of $350.51 million for the quarter, compared to analyst estimates of $349.05 million. Progyny had a return on equity of 15.98% and a net margin of 6.00%. Progyny’s revenue was up 5.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.19 earnings per share. Progyny has set its Q3 2026 guidance at 0.500-0.520 EPS and its FY 2026 guidance at 2.040-2.100 EPS. On average, analysts predict that Progyny will post 1.25 EPS for the current fiscal year.

Insider Activity at Progyny

In other Progyny news, EVP Allison Swartz sold 3,903 shares of the stock in a transaction on Wednesday, September 23rd. The stock was sold at an average price of $26.10, for a total transaction of $101,868.30. Following the sale, the executive vice president owned 75,816 shares in the company, valued at approximately $1,978,797.60. This represents a 4.90% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Melissa B. Cummings sold 1,879 shares of the firm’s stock in a transaction on Wednesday, October 14th. The stock was sold at an average price of $28.00, for a total value of $52,612.00. Following the transaction, the chief operating officer directly owned 66,496 shares of the company’s stock, valued at $1,861,888. The trade was a 2.75% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 17,282 shares of company stock valued at $475,790. 9.90% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Progyny

A number of institutional investors have recently made changes to their positions in the stock. BlackRock Inc. purchased a new stake in shares of Progyny in the second quarter valued at $334,426,000. Fort Washington Investment Advisors Inc. OH boosted its stake in shares of Progyny by 46.9% during the first quarter. Fort Washington Investment Advisors Inc. OH now owns 2,693,393 shares of the company’s stock valued at $45,734,000 after acquiring an additional 859,289 shares during the last quarter. Bank of America Corp DE purchased a new stake in Progyny during the 2nd quarter worth about $17,264,000. William Blair Investment Management LLC purchased a new stake in Progyny during the 2nd quarter worth about $16,807,000. Finally, Danske Bank A S purchased a new stake in Progyny during the 2nd quarter worth about $15,243,000. 94.93% of the stock is owned by institutional investors and hedge funds.

Progyny Company Profile

Progyny, Inc is a benefits-management company focused on fertility and family-building care. The company works with employers to provide comprehensive benefits that help members access fertility treatments and related services through a network of specialized providers.

Its offerings include coverage and support for services such as in vitro fertilization, fertility testing, egg and sperm freezing, donor services, gestational surrogacy, and adoption. Progyny also provides pharmacy benefits through Progyny Rx, as well as personalized guidance intended to help members navigate treatment options, providers, and the broader family-building process.

Progyny primarily serves self-insured employers and their employees in the United States.